Results 1 to 10 of about 307,034 (149)

A Placebo-controlled Trial of Percutaneous Coronary Intervention for Stable Angina

New England Journal of Medicine, 2023
Background Percutaneous coronary intervention (PCI) is frequently performed to improve symptoms of stable angina. Whether PCI without background antianginal medication relieves angina beyond placebo remains unknown.
C. Rajkumar, Michael J. Foley, Fiyyaz Ahmed‐Jushuf, A. Nowbar, F. Simader, John R Davies, Peter O’Kane, Peter Haworth, Helen Routledge, T. Kotecha, R. Gamma, Gerald Clesham, Rupert Williams, Jehangir Din, S. Nijjer, Nick Curzen, Neil Ruparelia, M. Sinha, Jason N Dungu, Sashiananthan Ganesananthan, R. Khamis, Lal Mughal, Tim Kinnaird, R. Petraco, James Spratt, S. Sen, J. Sehmi, D. Collier, A. Sohaib, Thomas R. Keeble, Graham D. Cole, James P. Howard, Darrel P. Francis, M. Shun-shin, R. Al-Lamee   +34 more
semanticscholar   +1 more source

Mortality after coronary artery bypass grafting versus percutaneous coronary intervention with stenting for coronary artery disease: a pooled analysis of individual patient data [PDF]

The Lancet, 2018
Stuart J. Head, Milan Milojevic, Joost Daemen, Jung‐Min Ahn, Eric Boersma, Evald Høj Christiansen, Michaël Domanski, Michael E. Farkouh, Marcus Flather, Valentı́n Fuster, Mark A. Hlatky, Niels Ramsing Holm, Whady Hueb, Masoor Kamalesh, Young‐Hak Kim, Timo Mäkikallio, Friedrich W. Mohr, Grigorios Papageorgiou, Seung‐Jung Park, Alfredo E. Rodríguez, Joseph F. Sabik, Rod Stables, Gregg W. Stone, Patrick W. Serruys, A. Pieter Kappetein   +24 more
openalex   +2 more sources

Prognostic value of systemic inflammatory response index in patients with acute coronary syndrome undergoing percutaneous coronary intervention

Annals medicus, 2022
Background The systemic inflammatory response index (SIRI) is a novel inflammatory biomarker in many diseases. Objectives The aim of this study was to examine the association between SIRI and adverse events in patients with the acute coronary syndrome ...
K. Han, D. Shi, Lixia Yang, Zhijian Wang, Yue-ping Li, F. Gao, Yuyang Liu, Xiaoteng Ma, Yujie Zhou   +8 more
semanticscholar   +1 more source

Aspirin Versus Clopidogrel for Long-Term Maintenance Monotherapy After Percutaneous Coronary Intervention: The HOST-EXAM Extended Study

Circulation, 2022
Background: Long-term outcomes of antiplatelet monotherapy in patients who receive percutaneous coronary intervention are unknown. The HOST-EXAM (Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis–Extended Antiplatelet Monotherapy ...
Jeehoon Kang, Kyung-Woo Park, H. Lee, D. Hwang, Han-Mo Yang, S. Rha, J. Bae, N. Lee, S. Hur, J. Han, E. Shin, B. Koo, Hyo‐Soo Kim   +12 more
semanticscholar   +1 more source

Antiplatelet therapy after percutaneous coronary intervention.

EuroIntervention, 2022
Antiplatelet therapy is key to reducing local thrombotic complications and systemic ischaemic events among patients undergoing percutaneous coronary interventions (PCI), but it is inevitably associated with increased bleeding.
D. Angiolillo, M. Galli, J. Collet, A. Kastrati, M. O’Donoghue   +4 more
semanticscholar   +1 more source

Post-stenting fractional flow reserve vs coronary angiography for optimization of percutaneous coronary intervention (TARGET-FFR)

European Heart Journal, 2021
Aims  A fractional flow reserve (FFR) value ≥0.90 after percutaneous coronary intervention (PCI) is associated with a reduced risk of adverse cardiovascular events.
D. Collison, M. Didagelos, Muhammad Aetesam-ur-Rahman, S. Copt, R. McDade, P. McCartney, T. Ford, J. McClure, M. Lindsay, A. Shaukat, P. Rocchiccioli, R. Brogan, S. Watkins, M. McEntegart, R. Good, K. Robertson, P. O’Boyle, A. Davie, Adnan Khan, S. Hood, H. Eteiba, C. Berry, K. Oldroyd   +22 more
semanticscholar   +1 more source

Antithrombotic Therapy in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Undergoing Percutaneous Coronary Intervention: A North American Perspective: 2021 Update.

Circulation, 2021
A growing number of patients undergoing percutaneous coronary intervention (PCI) with stent implantation also have atrial fibrillation. This poses challenges for their optimal antithrombotic management because patients with atrial fibrillation undergoing
D. Angiolillo, Deepak L. Bhatt, C. Cannon, J. Eikelboom, C. Gibson, S. Goodman, C. Granger, D. Holmes, R. Lopes, R. Mehran, D. Moliterno, M. Price, J. Saw, J. Tanguay, D. Faxon   +14 more
semanticscholar   +1 more source

Calcium Modification Techniques in Complex Percutaneous Coronary Intervention

Circulation. Cardiovascular Interventions, 2021
Supplemental Digital Content is available in the text. Percutaneous coronary intervention is the most common mode of revascularization and is increasingly undertaken in high-risk subsets, including the elderly.
M. Shah, Osman Najam, R. Bhindi, Kalpa de Silva   +3 more
semanticscholar   +1 more source

Effects of Acute Colchicine Administration Prior to Percutaneous Coronary Intervention

Circulation. Cardiovascular Interventions, 2020
Supplemental Digital Content is available in the text. Background: Vascular injury and inflammation during percutaneous coronary intervention (PCI) are associated with increased risk of post-PCI adverse outcomes.
Binita Shah, M. Pillinger, Hua Zhong, B. Cronstein, Yuhe Xia, J. Lorin, Nathaniel R. Smilowitz, F. Feit, Nicole Ratnapala, N. Keller, S. Katz   +10 more
semanticscholar   +1 more source

Effects of Percutaneous Coronary Intervention on Death and Myocardial Infarction Stratified by Stable and Unstable Coronary Artery Disease

Circulation. Cardiovascular Quality and Outcomes, 2020
Supplemental Digital Content is available in the text. Background: In patients presenting with ST-segment–elevation myocardial infarction, percutaneous coronary intervention (PCI) reduces mortality when compared with fibrinolysis.
L. Chacko, J. P. Howard, C. Rajkumar, A. Nowbar, Christopher Kane, Dina Mahdi, Michael J. Foley, M. Shun-shin, G. Cole, S. Sen, R. Al-Lamee, D. Francis, Y. Ahmad   +12 more
semanticscholar   +1 more source